IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Aurinia Pharmaceuticals Inc. vs ROGERS CORP — Side-by-side quantitative comparison
AUPH and ROG are remarkably close in our quantitative rankings. Aurinia Pharmaceuticals Inc. holds a slight edge with a composite score of 61.8/100 (Hold) versus ROGERS CORP at 61.4/100 (Hold). With a spread of just 0.4 points, the difference is marginal — investors should weigh qualitative factors like management quality, competitive positioning, and industry outlook to make a final decision.
For the Quality factor — which measures profitability and business quality through metrics like ROE, gross margins, and capital efficiency — AUPH leads at 80/100, while ROG trails at 57/100 (AUPH: 80/100, ROG: 57/100). The 23-point gap indicates a meaningful difference in quality characteristics between these stocks.
For the Value factor — which evaluates whether a stock is cheap or expensive relative to its earnings, book value, and cash flows — AUPH leads at 81/100, while ROG trails at 75/100 (AUPH: 81/100, ROG: 75/100). The 6-point gap indicates a meaningful difference in value characteristics between these stocks.
On the Momentum factor, which captures price trends and institutional sentiment over the trailing 3-12 months, these stocks are closely matched (AUPH: 66/100, ROG: 64/100). The narrow 2-point spread suggests similar momentum profiles, so this factor alone is unlikely to be a decisive differentiator.
On the Investment factor, which assesses capital allocation quality including reinvestment rates and asset growth, these stocks are closely matched (ROG: 30/100, AUPH: 28/100). The narrow 2-point spread suggests similar investment profiles, so this factor alone is unlikely to be a decisive differentiator.
For the Stability factor — which measures financial health through leverage ratios and price volatility — AUPH leads at 79/100, while ROG trails at 69/100 (AUPH: 79/100, ROG: 69/100). The 10-point gap indicates a meaningful difference in stability characteristics between these stocks.
For the Short Interest factor — which tracks institutional bearish positioning and potential risk from elevated short selling — ROG leads at 65/100, while AUPH trails at 20/100 (ROG: 65/100, AUPH: 20/100). The 44-point gap indicates a meaningful difference in short interest characteristics between these stocks.
Based on our 6-factor model, Aurinia Pharmaceuticals Inc. (AUPH) is utilizing a stronger overall profile than ROG, with a Composite Score of 62 vs 61. The comparison is extremely close. While AUPH leads slightly on Quality, ROG remains a competitive alternative.
| Overall Rating | ||
| Composite Score | 62 | 61 |
| Rank | #522 | #565 |
| Stars | 3 / 5 | 3 / 5 |
| Action | Hold | Hold |
| Factor Scores | ||
| Quality | 80 | 57 |
| Value | 81 | 75 |
| Momentum | 66 | 64 |
| Stability | 79 | 69 |
| Investment | 28 | 30 |
| Short Interest | 20 | 65 |
| Valuation | ||
| P/E Ratio | 11.53 | 42.39 |
| P/B Ratio | 3.98 | 1.21 |
| P/S Ratio | 4.95 | 1.69 |
| EV/EBITDA | 11.37 | 12.44 |
| Dividend Yield | 0.0% | 0.0% |
| Profitability | ||
| ROE | 28.8% | 2.5% |
| ROA | 21.2% | 2.1% |
| Gross Margin | 88.9% | 33.5% |
| Operating Margin | 40.5% | 7.3% |
| Net Margin | 43.0% | 4.0% |
| Growth & Risk | ||
| Revenue Growth | 8.4% | 2.7% |
| Debt/Equity | 0.00 | 2.00 |
| Beta | 0.68 | 1.13 |
| Market | ||
| Market Cap | $1.45B | $1.46B |
Based on our 6-factor quantitative model, AUPH currently has the higher composite score (61.8/100, Hold) and ranks #522 in our universe. However, the "better" stock depends on your investment goals, risk tolerance, and time horizon. We recommend reviewing the full factor breakdown above before making a decision.
Our comparison analyzes six quantitative factors: Quality (profitability and business strength, 30% weight), Momentum (price trends, 25%), Value (valuation attractiveness, 15%), Investment (capital allocation, 10%), Stability (financial health, 10%), and Short Interest (institutional positioning, 10%). Each factor is scored 0-100 and combined into a composite score.
AUPH has the higher value score at 81/100 compared to ROG at 75/100. A higher value score indicates the stock trades at a more attractive valuation relative to its earnings, book value, and cash flows.
Our stock rankings and comparisons are updated daily using the latest available market data, financial statements, and price information. Factor scores reflect the most recent quarterly filings and trailing price data.